Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL27607866 | 0.92 | KMT2A (0.43) | HDAC1HDAC6NPC1LMNARAB9A | |
| SCHEMBL2456714 | 0.84 | GPR183 (0.46) | RAB9AGABRA1 | |
| SCHEMBL2460465 | 0.82 | SCN5A (0.40) | ALDH1A1GRM5 | |
| SCHEMBL5427032 | 0.78 | HDAC1 (0.62) | HDAC1HDAC6NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2456362 | 0.78 | USP30 (0.60) | NPC1LMNARAB9ASMN1; SMN2KDM4E | |
| SCHEMBL2459916 | 0.78 | NPC1 (0.54) | NPC1RAB9AKDM4EKMT2AALDH1A1 | |
| SCHEMBL2458950 | 0.78 | CA12 (0.53) | NPC1LMNARAB9AKDM4EKMT2A | |
| SCHEMBL2459809 | 0.78 | RAB9A (0.40) | NPC1LMNARAB9AKMT2AALDH1A1 | |
| SCHEMBL3394258 | 0.78 | MTNR1A (0.60) | HDAC1HDAC6KDM4EGRM5 | |
| SCHEMBL3394439 | 0.78 | MTNR1A (0.60) | HDAC1HDAC6KDM4EGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534277-B1 | ACYLATED, HETEROARYL-CONDENSED CYCLOALKENYLAMINES AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2011-09-14 | — | — | EP | disclosed |
| EP-1534277-B1 | ACYLATED, HETEROARYL-CONDENSED CYCLOALKENYLAMINES AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2011-09-14 | — | — | EP | disclosed |
| US-7105513-B2 | Cardiovascular disorders; strokes; hypotensive agents | SANOFI-AVERTIS DEUTSCHLAND GMBH (DE) | 2006-09-12 | — | — | US | disclosed |
| EP-1534277-A1 | ACYLATED, HETEROARYL-CONDENSED CYCLOALKENYLAMINES AND THEIR USE AS PHARMACEUTICALS | Aventis Pharma Deutschland GmbH (DE) | 2005-06-01 | — | — | EP | disclosed |
| US-20040092513-A1 | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-05-13 | — | — | US | disclosed |
| WO-2004014372-A1 | ACYLATED, HETEROARYL-CONDENSED CYCLOALKENYLAMINES AND THEIR USE AS PHARMACEUTICALS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092513-A1 | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals | LIPG, AADAC, AANAT | HDAC1 35/4885HDAC6 29/4885NPC1 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.